Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy

Hernández, Caridad Marín; Piñero-Madrona, Antonio; Vázquez, Pedro José Gil; Fernández, Pascual; Merino, Guadalupe Ruíz; Alonso-Romero, José Luis; Paricio, Pascual Parrilla

doi:10.1007/s12094-017-1732-0

Cited by 98 publications

(83 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies including All BC Molecular Subtypes: DFS was the primary objective in six studies [23][24][25][26]28,29]. Only two (33%) found that a higher NLR was correlated with a shorter DFS in the univariate analysis [25,26].…”

Section: Results On Nlr and Dfsmentioning

confidence: 99%

“…(1) Patients Receiving Neo-Adjuvant Therapy Ten studies reported data on NLR as a predictive or prognostic factor in patients receiving neo-adjuvant therapy [22][23][24][25][26][27][28][29][30][31]. Among these studies, eight included patients with all molecular subtypes [22][23][24][25][26][27][28][29], one included only patients with triple negative BC (TNBC) [31] and the last one included only patients with hormone receptor-positive/HER2-negative BC [30]. The NLR cut-off for the statistical analyses was between 1.7 and 3.33, and was computed by a receiver operating characteristic (ROC) curve analysis in all studies.…”

Section: In Early Bcmentioning

confidence: 99%

“…Five studies reported data on Asian populations [23,25,28,30,31]. In nine articles, the neo-adjuvant therapy protocols were described, and were based on anthracycline and/or taxane [23][24][25][26][27][28][29][30][31]. (Table 1).…”

Section: In Early Bcmentioning

confidence: 99%

See 2 more Smart Citations

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review

Corbeau

Jacot

Guiu

2020

Cancers

View full text Add to dashboard Cite

Inflammatory blood markers (IBM), such as the neutrophil to lymphocyte ratio (NLR), have emerged as potential prognostic factors in various cancers, including breast cancer (BC), potentially allowing an easy, minimally invasive evaluation of a given cancer‘s prognosis and treatment outcome. We report here a systematic overview of the published data evaluating NLR as a prognostic factor or predictive factor for pathological complete response (PCR) and toxicity in early and advanced BC. A total of 45 articles were identified. NLR was found to be an independent prognostic factor for survival in most of the adjuvant treatment studies. However, no significant correlation was found between survival and NLR for early BC patients receiving neo-adjuvant chemotherapy (NACT) and advanced BC patients. Most studies failed to find a significant correlation between NLR and PCR after NACT. Finally, some data showed that IBM could be predictive of chemotherapy-related toxicity.

show abstract

Section: Results On Nlr and Dfsmentioning

confidence: 99%

Section: In Early Bcmentioning

confidence: 99%

See 1 more Smart Citation

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review

Corbeau

Jacot

Guiu

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…As a potential epiphenomenon of chemotherapy-induced immunomodulation, we also studied NLR which has been reported to be associated with prognosis and response to chemothera- peutic agents in breast cancer in several studies [19][20][21][22]. In the present study, NLR was dynamically analyzed during eribulin treatment: at baseline, at best response and at progression.…”

Section: Discussionmentioning

confidence: 97%

Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients

et al. 2018

View full text Add to dashboard Cite

Objectives: Predictive factors of response to eribulin are lacking. We aimed to investigate the activity and safety of eribulin in a real-world population of metastatic breast cancer (MBC) patients and to identify possible predictive factors of progression-free survival (PFS) and objective response. Methods: We retrospectively analyzed 71 eribulin-treated MBC patients. Best response rate, PFS, and adverse events (AEs) were evaluated. The impact of different clinical-pathological factors on PFS was evaluated using the Cox proportional hazards model. Predictive factors of response were identified by discriminant function analysis (DFA). Results: Median PFS was 3.75 months (95% CI, 2.39–4.48); 12 patients (16.90%) achieved partial response (PR), 27 (38.03%) stable disease. The most common AEs were fatigue (25.83%), neutropenia (16.56%), and peripheral neuropathy (13.91%). A worse performance status (p = 0.025) and a higher number of metastatic organ sites (p = 0.011) were associated with a worse PFS under eribulin. Overall, in the DFA-predictive model, neutrophil-to-lymphocyte ratio at baseline, estrogen receptor, Ki67, histology, and age were predictive of PR with 100% accuracy. Conclusions: Activity and safety profiles of eribulin were consistent with literature data. Performance status and number of metastatic sites were predictive factors of PFS. DFA could be a promising tool to discriminate responses to eribulin among MBC patients.

show abstract

“…37,38 Some studies have shown that inflammatory markers and immune-based prognostic indexes were used to evaluate the prognosis of breast cancer, such as NLR, d-NLR, MLR/LMR, and PLR. [39][40][41] However, these inflammatory markers were associated with poor prognosis in breast cancer patients, and the potential mechanisms were not yet clear. The SIRI based on three inflammatory cells, such as neutrophil, monocyte, and lymphocyte, and can fully evaluate the balance between host immune and inflammatory condition.…”

Section: Discussionmentioning

confidence: 99%

<p>Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator</p>

Chen¹,

Kong²,

Wang³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background and Objective: Systemic inflammation response index (SIRI=N×M/L), based on neutrophil (N), monocyte (M), and lymphocyte (L) counts, is used to predict the survival of patients with malignant tumors and can fully evaluate the balance between host immune and inflammatory condition. The present study is aimed to evaluate the potential prognostic significance of SIRI in patients with breast cancer undergoing neoadjuvant chemotherapy. Subjects and Methods: A total of 262 breast cancer patients treated with neoadjuvant chemotherapy were enrolled in this retrospective study. The optimal cutoff value of SIRI by receiver operating characteristic curve stratified patients into low SIRI (<0.85×10 9 /L) group and high SIRI (≥0.85×10 9 /L) group. The associations between breast cancer and clinicopathological variables by SIRI were determined by chi-square test or Fisher's exact test. Kaplan-Meier plots and log-rank test were used to evaluate the clinical outcomes of disease-free survival (DFS) and overall survival (OS). Univariate and multivariate Cox proportional hazards regression models were used to analyze the prognostic value of SIRI. The toxicity of neoadjuvant chemotherapy was evaluated by the National Cancer Institute Common Toxicity Criteria (NCICTC). Results: The results were shown that SIRI had prognostic significance by optimal cutoff value of 0.85×10 9 /L on DFS and OS in univariate and multivariate Cox regression survival analyses. Compared with patients who had high SIRI, patients with low SIRI had longer DFS and OS (41.27 vs 30.45 months, HR: 1.694, 95% CI: 1.128-2.543, P=0.011; 52.86 vs 45.75 months, HR: 1.288, 95% CI: 0.781-3.124, P=0.002, respectively). The patients with low SIRI had better 3-, 5-, and 10-year rates of DFS and OS than those with high SIRI. The common toxicities after neoadjuvant chemotherapy were hematologic and gastrointestinal reaction, and the SIRI had no significance on toxicities of all enrolled patients, excepted diarrhea. In patients without neural invasion, those with low SIRI had better prognosis and lower recurrence rates than those with high SIRI.Conclusion: Pretreatment SIRI with the advantage of repeatable, convenient, and non-invasive is a useful prognostic indicator for breast cancer patients who received neoadjuvant chemotherapy and is a promising biomarker for breast cancer on treatment strategy decisions.

show abstract

Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy

Abstract: High LMR and low NLR can be considered as favourable prognostic factors in BC patients treated with nCT.

Cited by 98 publications

References 31 publications

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review

Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients

<p>Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator</p>

Contact Info

Product

Resources

About